Johnson & Johnson Common Stock Dividends Paid 2010-2024 | JNJ

Johnson & Johnson annual/quarterly common stock dividends paid history and growth rate from 2010 to 2024. Common stock dividends paid can be defined as the cash outflow for dividends paid on a company's common stock
  • Johnson & Johnson common stock dividends paid for the quarter ending September 30, 2024 were $-8.839B, a 0.74% decline year-over-year.
  • Johnson & Johnson common stock dividends paid for the twelve months ending September 30, 2024 were $-29.332B, a 0.78% decline year-over-year.
  • Johnson & Johnson annual common stock dividends paid for 2023 were $-11.77B, a 0.75% increase from 2022.
  • Johnson & Johnson annual common stock dividends paid for 2022 were $-11.682B, a 5.89% increase from 2021.
  • Johnson & Johnson annual common stock dividends paid for 2021 were $-11.032B, a 5.26% increase from 2020.
Johnson & Johnson Annual Common Stock Dividends Paid
(Millions of US $)
2023 $-11,770
2022 $-11,682
2021 $-11,032
2020 $-10,481
2019 $-9,917
2018 $-9,494
2017 $-8,943
2016 $-8,621
2015 $-8,173
2014 $-7,768
2013 $-7,286
2012 $-6,614
2011 $-6,156
2010 $-5,804
2009 $-5,327
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $381.247B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $765.205B 79.26
Novo Nordisk (NVO) Denmark $494.212B 37.72
AbbVie (ABBV) United States $356.397B 18.76
Merck (MRK) United States $257.460B 17.08
Novartis AG (NVS) Switzerland $223.573B 14.86
AstraZeneca (AZN) United Kingdom $205.476B 18.31
Pfizer (PFE) United States $158.619B 10.85
Sanofi (SNY) $134.124B 12.15
Innoviva (INVA) United States $1.216B 6.75